These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12876618)

  • 1. Estrogen and C-reactive protein: does an alternate route lead to a more attractive destination?
    Duvernoy C
    Thromb Haemost; 2003 Jul; 90(1):1-2. PubMed ID: 12876618
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein.
    Lacut K; Oger E; Le Gal G; Blouch MT; Abgrall JF; Kerlan V; Scarabin PY; Mottier D;
    Thromb Haemost; 2003 Jul; 90(1):124-31. PubMed ID: 12876635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estradiol associated with lower thrombotic risk than conjugated equine estrogens when used as oral HRT.
    Brown S
    Menopause Int; 2013 Dec; 19(4):145. PubMed ID: 24479171
    [No Abstract]   [Full Text] [Related]  

  • 4. The insulin-like growth factor-I system and hormone replacement therapy.
    Cardim HJ; Lopes CM; Giannella-Neto D; da Fonseca AM; Pinotti JA
    Fertil Steril; 2001 Feb; 75(2):282-7. PubMed ID: 11172828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: The ESTHER study.
    Canonico M; Olié V; Carcaillon L; Tubert-Bitter P; Scarabin PY;
    Thromb Haemost; 2008 Jan; 99(1):246-8. PubMed ID: 18217166
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung cancer and hormone replacement therapy.
    Canonico M; Plu-Bureau G; Scarabin PY
    Lancet; 2010 Jan; 375(9709):117; author reply 118-9. PubMed ID: 20109882
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of transdermal estradiol and oral conjugated equine estrogen on C-reactive protein in retinoid-placebo trial in healthy women.
    Wakatsuki A; Okatani Y; Fukaya T
    Circulation; 2003 May; 107(18):e127-8; author reply e127-8. PubMed ID: 12742976
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen.
    Modena MG; Bursi F; Fantini G; Cagnacci A; Carbonieri A; Fortuna A; Rossi R
    Am J Med; 2002 Sep; 113(4):331-4. PubMed ID: 12361820
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and benefit considerations for menopausal hormone therapy.
    Pickar JH; Archer DF; Kagan R; Pinkerton JV; Taylor HS
    Expert Opin Drug Saf; 2017 Aug; 16(8):941-954. PubMed ID: 28664754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose hormone therapy in postmenopausal women in China.
    Zang H; Shi H; Speroff L
    Climacteric; 2010 Dec; 13(6):544-52. PubMed ID: 19938946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens].
    Winkler UH; Krämer R; Kwee B; Schindler AE
    Zentralbl Gynakol; 1995; 117(10):540-8. PubMed ID: 7491837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung cancer and hormone replacement therapy.
    Barton M; Meyer MR; Bolton JL; Prossnitz ER
    Lancet; 2010 Jan; 375(9709):117-8; author reply 118-9. PubMed ID: 20109881
    [No Abstract]   [Full Text] [Related]  

  • 14. [Are hormone substitution and vitamins dangerous for elderly women with heart diseases?].
    Schenck-Gustafsson K
    Lakartidningen; 2003 May; 100(20):1784-6. PubMed ID: 12806858
    [No Abstract]   [Full Text] [Related]  

  • 15. The WHI estrogen-alone trial--do things look any better?
    Hulley SB; Grady D
    JAMA; 2004 Apr; 291(14):1769-71. PubMed ID: 15082705
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women.
    Murkes D; Conner P; Leifland K; Tani E; Beliard A; Lundström E; Söderqvist G
    Fertil Steril; 2011 Mar; 95(3):1188-91. PubMed ID: 21067727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HRT: forever or never?
    Corson SL
    Int J Fertil Womens Med; 2002; 47(4):150-1. PubMed ID: 12199410
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.
    Langer RD
    Am J Epidemiol; 2009 Mar; 169(6):784-5; author reply 785-6. PubMed ID: 19208722
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.
    Ettinger B; Pressman A; Bradley C
    Menopause; 1998; 5(3):152-6. PubMed ID: 9774760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.
    Wood C; Cline M
    J Natl Cancer Inst; 2008 Sep; 100(18):1335; author reply 1335-6. PubMed ID: 18780867
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.